Use of ultrapure dialysate in reduction of chronic inflammation during hemodialysis

Chronic inflammation contributes to the pathogenesis of several complications of hemodialysis therapy. It is thought that backfiltration of bacteria-derived contaminations during dialysis may induce a chronic inflammatory state. High-sensitivity C-reactive protein (hs-CRP) is one of the tools which can take a hold on such a chronic inflammatory condition. We examined the effect of ultrapure dialysate which contributes to chronic inflammation with hs-CRP and tried to reduce endotoxin (ET) levels at the end of the dialysate from 70 EU/l to <1.0 EU/l (ultrapure dialysate). Other dialysis conditions, except ET level, were fixed. We investigated the hs-CRP of 23 patients receiving regular dialysis before the use of ultrapure dialysate and 1 year after use of it prospectively. The data showed a significant decrease in the median value of the hs-CRP from 0.16 to 0.07 mg/dl (p < 0.05). The value of serum beta(2)-microglobulin decreased from 33.2 to 28.4 mg/dl (p < 0.01) and the hemoglobin level increased from 10.0 to 11.0 g/dl (p < 0.05). These results indicate that even a dialysate containing 70 EU/l of ET level may induce a chronic inflammatory state. hs-CRP is a very useful marker of chronic inflammation and the use of ultrapure dialysate is necessary to improve a chronic inflammatory state. The targeted ET level at the end of the dialysate should be set at < or = 1.0 EU/l.     

Microbiological survey of dialysate: vantage of use of sterile bag concentrate

Haemodialysed patients are exposed to nearly 400 litres of dialysis water weekly. The bacterial contamination of treated dialysate and water induces acute pyrogenic reactions or chronic damage and cytokine activation. The aim of this study was to value the microbiological parameters of dialysis water and dialysate of our monitors by bacterial culture (measured as colony forming units [CFU]) of water samples at 37 degrees C after 48 hours, at 22 degrees C after 72 hours and after seven days, and by measuring endotoxin levels (endotoxin units [EU]). In our centre, there are 16 monitors (6 monitors use sterile dialysate fluid and 10 monitors use non sterile dialysate fluid). The chemicals used for disinfection are chlorine and paracetic acid. Water samples were taken under sterile procedures every three months for a year. No bacteria were found in the samples of water of the dialysis ring; EU were lower than the limit value of 0.25 EU/ml fixed by the European Pharmacopoeia. The concentration of CFU and EU of the dialysate, taken from monitors with a sterile bag, were lower than those of other monitors (p < 0.05 t Student test). However, the levels of CFU/ml and EU/ml of dialysate samples, taken from monitors with a non-sterile bag, were lower than the guideline value of the European Pharmacopoeia (v.n. CFU < 50 CFU/ml and EU < 0.05 EU/ml). Frequent examination of CFU and EU is essential to reduce the damage caused by the use of contaminated water, therefore the goal of future dialytic techniques will be the use of "sterile dialysate".     

Ultrapure dialysate reduces plasma levels of beta2-microglobulin and pentosidine in hemodialysis patients

BACKGROUND: beta2-Microglobulin (beta2MG) and carbonyl stress are reported to contribute to the development of dialysis-related amyloidosis. The aim of this study was to determine whether the purity of dialysate affects plasma levels of beta2MG and pentosidine (a surrogate marker of carbonyl stress) in hemodialysis patients. METHODS: Sixteen patients on hemodialysis with a polysulfone membrane participated in this study. We switched the dialysate from conventional dialysate (endotoxin level 0.055-0.066 endotoxin units (EU)/ml) to ultrapure dialysate (endotoxin level <0.001 EU/ml), followed patients for 6 months, and then switched back to conventional dialysate once again. Plasma levels of beta2MG, pentosidine, CRP and interleukin-6 (IL-6) were determined before the switch to ultrapure dialysate, 1 and 6 months after the switch to ultrapure dialysate, and 1 month after the switch back to conventional dialysate. RESULTS: The switch from conventional to ultrapure dialysate significantly decreased plasma levels of beta2MG, from 30.1 +/- 1.4 to 27.1 +/- 1.4 mg/dl (p < 0.05) and pentosidine, from 1,535.8 +/- 107.5 to 1,267.6 +/- 102.9 nmol/l (p < 0.01) after 1 month of use. The change of dialysate also significantly decreased plasma levels of CRP, from 0.28 +/- 0.09 to 0.14 +/- 0.05 mg/dl (p < 0.05) and IL-6, from 9.4 +/- 2.7 to 3.5 +/- 0.8 pg/ml (p < 0.01) over the 1-month period. These changes in plasma levels of beta2MG, pentosidine, CRP and IL-6 were maintained over 6 months after switching to ultrapure dialysate and returned to basal levels by switching back to a conventional dialysate. CONCLUSIONS: Ultrapure dialysate decreases plasma levels of beta2MG, pentosidine and inflammatory markers in hemodialysis patients. The use of ultrapure dialysate might be useful in preventing and/or treating complications of dialysis, such as dialysis-related amyloidosis, atherosclerosis and malnutrition.     

雌激素替代治疗对绝经后妇女冠心病者血脂代谢及抗氧化作用的研究

对32例绝经后妇女（PMW）冠心病患者（CHD组）进行雌激素替代治疗（ERT），以观察对其血脂代谢及机体抗氧化水平的影响。另选取绝经后健康妇女30例为对照组。CHD组口服尼尔雌醇（CEE3）每月2次，每次2mg，连用6个月，分别于用药前、用药后3个月及6个月检测总胆固醇（TC）、甘油三酯（TG）、高密度脂蛋白胆固醇（HDL－C）、低密度脂蛋白胆固醇（LDL－C）、脂蛋白（a）［LP（a）］、氧化修饰低密度脂蛋白（Ox－LDL）、丙二醛（MDA）及超氧化物歧化酶（SOD）。结果表明ERT前CHD组与对照组比较LP（a）、Ox－LDL及MDA水平明显升高（P＜0．05），而SOD总活力显著降低；CHD组于ERT后TC无明显变化，TG呈升高趋势（P＞0.05），而LDL-C、TC／HDL－C和LDL－C／HDL－C显著下降（P＜0．01），LP（a）也明显降低（P＜0．05），而HDL－C显著上升（P＜0．01）；血浆Ox－LDL、血清MDA显著下降（P＜0．01），血清SOD总活力明显上升（P＜0．05），提示ERT不仅能显著改善PMW之CHD患者血脂紊乱，而且能有效地提高机体抗氧化水平。     

X综合征患者血浆内皮素、一氧化氮浓度变化及其临床意义

目的：本研究以生化指标观察并探讨血管内皮功能与Ｘ综合征的联系。方法：采用放射免疫法、酶联免疫吸附法和分光光度法检测Ｘ综合征患者血浆内皮素、氧化型低密度脂蛋白和一氧化氮（以亚硝酸盐表示）水平，同时与冠心病患者和（或）健康人作对照分析。结果：Ｘ综合征患者血浆内皮素、一氧化氮水平较健康人升高，血浆内皮素／一氧化氮比值亦增大，而血浆氧化型低密度脂蛋白水平在正常范围。结论：Ｘ综合征患者血浆内皮素增高，血浆内皮素／一氧化氮比例可能失衡，从而导致血管舒缩状态异常。     

冠心病与颈动脉斑块及丙二醛化低密度脂蛋白的相关性研究

目的研究冠心病患者冠心病与颈动脉内-中膜厚度(CCA-IMT)、斑块指数及丙二醛化低密度脂蛋白(MDA-LDL)的相关性。方法收集冠状动脉造影的冠心病患者82例,根据斑块形态,冠心病患者分为3组,即Ⅰ型病变(表面光滑)组(n=31),Ⅱ型病变(表面不规则)组(n=a2)及Ⅲ型病变(长段不规则)组(n=19),冠状动脉造影正常的25例为对照组纳入研究。采用高频超声探测各组双侧颈动脉 IMT 和软斑指数,硬斑指数及总斑块指数,以及测定血浆 MDA-LDL 含量。结果 (1)冠心病各组(包括Ⅰ型、Ⅱ型、Ⅲ型病变组)CCA-IMT、软斑 PI、硬斑PI、总斑 PI 与对照组相比明显增高(均P<0.01);冠心病Ⅱ型病变组软斑 PI、总斑 PI 与Ⅰ型、Ⅲ型病变组相比明显增高(P<0.01);Ⅱ型病变组血浆 MDA-LDL 含量与Ⅰ型、Ⅲ型病变组及照组相比明显增高(P<0.01)。(2)Ⅱ型病变组 MDA-LDL 含量与软斑 PI、总斑 PI 呈正相关(r=0.63,P<0.01;r=0.51,P<0.05)。结论通过颈动脉超声检测,颈动脉斑块(特别是软斑)的检出,结合血浆 MDA-LDL 含量,可以初步预测冠心病患者冠状动脉斑块的不稳定。     

透析用水及透析液中内毒素污染状况的分析

目的　研究透析用水、透析液内毒素及细菌污染状况。方法　对北京１８ 家医院透析室反渗水、透析液用改良鲎试验检测内毒素,用血琼脂培养基做细菌培养,用ＥＬＩＳＡ法测定患者血浆白介素（ＩＬ）１、ＩＬ６ 及肿瘤坏死因子（ＴＮＦ）α。结果　反渗水内毒素为（０．１１６±０ ．０６３） ＥＵ／ｍｌ;细菌培养有两家医院阳性,均为１００ ＣＦＵ／ｍｌ。Ｂ浓缩透析液内毒素为（０．４６ ±０．３５） ＥＵ／ｍｌ,而Ａ浓缩透析液内毒素仅（０．０９１±０ ．０８４） ＥＵ／ｍｌ（Ｐ＜０ ．００１） ;Ｂ浓缩透析液细菌培养１１ 家阳性,其中８ 家≥２ ０００ ＣＦＵ／ｍｌ,Ａ浓缩透析液细菌培养阳性仅３ 家,均＜ ２ ０００ ＣＦＵ／ｍｌ。１６ 例患者中有５ 例透析器入口透析液内毒素＞０．５ ＥＵ／ｍｌ,且透后血ＩＬ６ 及ＴＮＦα显著增高。结论　目前透析用水及透析液存在内毒素及细菌的污染,定期检测反渗水、透析液的内毒素水平及进行细菌培养,定期消毒反渗水装置及透析液容器,对减少热源反应至关重要。     

氧化型低密度脂蛋白促进类风湿关节炎成纤维样滑膜细胞增殖及炎性因子mRNA表达的研究

目的:探讨氧化型低密度脂蛋白(Ox-LDL)对RA患者成纤维样滑膜细胞(FLS)增殖及炎性因子mRNA表达的影响。方法:采用组织块贴壁法分离培养RA-FLS,4~6代细胞用于后续实验。不同浓度的人Ox-LDL刺激RA-FLS 24 h,MTS实验检测细胞增殖情况,实时(RT)-PCR法检测炎性因子IL-6、TGF-β、IL-8、TNF-α及清道夫受体CD36、结合磷脂酰丝氨酸和氧化脂蛋白的清道夫受体(SR-PSOX)mRNA表达水平。siRNA特异性敲减SR-PSOX,RT-PCR法检测敲减效果,同时验证SR-PSOX基因敲减后各相关基因的表达。统计学分析采用t检验,F检验。结果:不同浓度Ox-LDL(10、25、50μg/ml)可明显促进RA-FLS的增殖,其吸光度(A)值(490 nm)分别为:(1.04±0.15)、(1.05±0.14)、(1.00±0.10),均高于对照组(0.81±0.04),差异有统计学意义(F=4.737,P<0.01)。在炎性因子mRNA表达方面,与对照组相比较,50μg/ml和100μg/ml Ox-LDL可显著促进IL-6 mRNA的表达(F=14.709,P<0.01);不同浓度Ox-LDL均可抑制RA-FLS中TGF-βmRNA的表达(F=299.074,P<0.01),而对IL-8、TNF-αmRNA的表达无明显影响。进一步的机制探讨发现Ox-LDL可促进RA-FLS高表达SR-PSOX(F=68.636,P<0.01),并抑制CD36的表达(F=18.085,P<0.01)。siRNA特异性敲减SR-PSOX,可显著抑制Ox-LDL刺激RA-FLS表达IL-6 mRNA(t=3.875,P<0.01),而对TGF-βmRNA表达水平无显著影响(t=-0.193,P>0.05)。结论:Ox-LDL可显著促进RA-FLS的增殖,同时Ox-LDL可能通过上调SR-PSOX的表达促进了IL-6 mRNA的表达,提示Ox-LDL可能参与了RA的滑膜增生及炎症持续过程。     

抗人丙二醛修饰低密度脂蛋白单克隆抗体的制备和免疫学性质

本文报道两株抗丙二醛修饰的低密度脂蛋白单克隆抗体（ＨＭＬ、ＨＭＬ２），两者均有较高的抗体效价，抗体类型为ＩｇＧ２ａ。单抗相加实验表明，ＨＭＬ１和ＨＭＬ２识别同一抗原位点。竞争性ＢＡ－ＥＬＩＳＡ实验显示：ＨＭＬ１能够识别丙二醛修饰的低密度脂蛋白、丙二醛清蛋白、丙二醛聚赖氨酸。但与天然低密度脂蛋白无交叉反应。推测ＨＭＬ１抗原位点与低密度脂蛋白在修饰过程中丙二醛和载脂蛋白Ｂ上的赖氨酸残基形成的共价结合物     

Bacteriological Qualities of Dialysis Fluid in Japan as of 31 December 2006

The Japanese Society for Dialysis Therapy (JSDT) collected the data from 3488 dialysis facilities about the status of bacteriological qualities and quality controls for dialysis fluid as of 31 December 2006. The data included the endotoxin (ET) levels, bacterial counts and usage of ET retentive filters (ETRFs). It was found that ET level measurements were performed in 2873 facilities (82.4%). The JSDT standard for ET level in dialysis fluid (<0.050 EU/mL) was achieved in 89.0%, and an ET level less than 0.001 EU/mL was achieved in 29.8%; however, bacterial counts were examined in only 1049 facilities (34.1%). The JSDT standard for the bacterial cell count in dialysis fluid (<100 cfu/mL) was achieved in 96.9%, and a count of 0.1 cfu/mL, which guarantees ultra‐pure dialysis fluid, was achieved in 48.4%. ETRFs were installed in 78.5% of all facilities and in 53.4% of all dialysis machines. Although the JSDT standard is the most stringent in the world, the compliance rate was excellent. Bacteriological water qualities of dialysis fluid are extremely high in most Japanese dialysis facilities and this might have a close relationship to the high dialysis patient survival rate in Japan.     

依那普利对高血压患者血浆氧化修饰低密度脂蛋白的影响

目的 :观察高血压患者血浆氧化修饰低密度脂蛋白(Ox- L DL)水平 ,及化学结构无巯基的血管紧张素转换酶抑制剂 (ACEI)降压的同时 ,是否会对 Ox- L DL产生影响。方法 :选择高血压患者 5 6例及年龄、性别相当的正常对照者30例。高血压组口服依那普利 5 mg,每日二次 ,共 16周 ,于服药前、服药后 8周及 16周 ,分别采集清晨空腹静脉血 ,检测血清甘油三脂 (TG)、胆固醇 (TC)及血浆 Ox- L DL、丙二醛(MDA)、过氧化物歧化酶 (SOD)及谷胱甘肽过氧化物酶GSH- Px。结果 :高血压组 Ox- L DL、MDA显著高于对照组 (P<0 .0 1) ,SOD、GSH- Px低于对照组 (P<0 .0 1)。服药 8周时无显著变化 ,16周时 Ox- L DL(P<0 .0 5 )及 MDA(P<0 .0 1)显著降低 ,TG、TC稍有下降 ,GSH- Px、SOD稍有升高 ,但无统计学意义。结论 :高血压病患者血浆 Ox- L DL 显著增高 ,口服依那普利可在一定程度阻止 L DL的氧化修饰     

Association between tissue factor, its pathway inhibitor and oxidative stress in peritoneal dialysis patients.

The abnormalities of tissue factor and its inhibitor system, increased oxidative stress and the presence of diabetes may be involved in the mechanism of thrombotic complication in peritoneal dialysis patients. We compared the plasma levels of tissue factor, its inhibitor and markers of oxidative stress (malondialdehyde and Cu/Zn superoxide dismutase) in 16 diabetic peritoneal dialysis patients, 40 nondiabetic peritoneal dialysis patients, and 20 healthy control individuals. We tried to establish whether there is an association between tissue factor, its inhibitor and oxidative stress in these patients. Compared with the control individuals, the patients both with and without diabetes showed a significant increase in plasma concentrations of Cu/Zn superoxide dismutase (P < 0.01 and P < 0.001, respectively), malondialdehyde (both P < 0.05), tissue factor (both P < 0.001) and tissue factor pathway inhibitor (P < 0.01 and P < 0.001, respectively). The differences in oxidative status and coagulation parameters between patients with and without diabetes were not statistically significant. In all peritoneal dialysis patients, both tissue factor and its inhibitor were positively related to Cu/Zn superoxide dismutase (r = 0.310, P < 0.05 and r = 0.460, P < 0.001, respectively) and malondialdehyde levels (r = 0.337, P < 0.05 and r = 0.361, P < 0.01, respectively). Our data suggest a relationship between increased oxidative stress and elevated tissue factor and its inhibitor levels in peritoneal dialysis patients, particularly those with diabetes.     

诺衡和泛硫乙胺对糖尿病患者抗脂质过氧化的随机对照研究

作者采用随机对照的方法,观察了调脂药诺衡和泛硫乙胺对糖尿病患者脂质过氧化的影响。结果表明,诺衡可使糖尿病患者血中的过氧化脂和过氧化-低密度脂蛋白明显降低,分别降低41.4％相43.2％,且优于泛硫乙胺。     

Breath ethane peaks during a single haemodialysis session and is associated with time on dialysis

There is growing evidence that oxidative stress is increased in haemodialysis patients and that dialysis per se is a contributory factor. The elevated oxidant stress, a result of increased production of reactive oxidant species (ROS), may be due to increased pro-inflammatory activity and reduced antioxidant mechanisms. ROS are transitory molecules and therefore surrogate markers of oxidant damage are required. Identification of potential causes of oxidative damage such as dialyser membranes or dialysate has been proposed and therefore assessment of oxidative damage during a single dialysis session would be of interest. We have used breath ethane, a widely accepted marker of oxidative stress, to investigate the cause and extent of the resulting oxidative damage during single dialysis sessions. Our study involved assessment of breath ethane levels during haemodialysis in an end-stage renal failure haemodialysis population (n = 24). Breath samples were collected using discrete sampling techniques and were subsequently analysed using laser spectroscopy. Each patient adopted the role of longitudinal control in this study and his or her breath ethane level was monitored regularly during the dialysis session. Significant breath ethane elevation was observed at the beginning (within the first 10 min) of each dialysis session. This paper provides an in-depth statistical analysis and clinical discussion of the recent findings. A regression analysis of the collected breath ethane data showed a trend towards increased ethane levels for patients on dialysis for a shorter duration of time (r = 0.656, R-Sq = 43.3%, p = 0.001). Multiple linear regression was undertaken to further assess these associations and revealed that peak ethane levels were significantly and independently associated with time period on dialysis (p < 0.000), vascular access (p = 0.013) and male sex (p = 0.005). However, whilst diabetes status had demonstrated a correlation with peak ethane levels (0.525, p = 0.008) this was not independent of vascular access status. This multivariate linear model was significantly associated with Ln peak ethane levels (S = 0.744, R-Sq = 80.8%). The observed rapid rise in oxidative stress during the first few minutes after commencement of dialysis gives new insight into the dynamics of the oxidative damage resulting from dialysis treatment.     

Response of alkaline phosphatase to zinc repletion in hypozincemic hemodialysis patients

The response of serum alkaline phosphatase (AP), a zinc-dependent metalloenzyme, to zinc administration via the dialysate (400 micrograms/l) was examined in 14 hypozincemic (less than 30th percentile of dialysis patients) hemodialysis patients and in 14 placebo-treated matched dialysis control patients. Plasma zinc and serum AP were measured three times: prior to, once weekly during (5 weeks), and 2 weeks after addition of zinc to the dialysate. The serum zinc levels remained stable in placebo-treated controls (initial 87.7 +/- 12.5; final 78.6 +/- 8.3 micrograms/dl) and increased in zinc-treated patients (initial 76.4 +/- 8.3; 5th week 96.9 +/- 13.3; 2 weeks after zinc withdrawal 82.3 +/- 12.2 micrograms/dl). There was a slight increase of AP with time in placebo controls (initial 90.2 +/- 26.5; 5th week 100 +/- 29 U/l) and a more pronounced increase in zinc-treated patients (initial 90.8 +/- 19.9; 5th week 113 +/- 20.9 U/l). The difference between the two groups was marginally significant (p less than 0.05; analysis of variance). It is concluded that zinc repletion via dialysate with documented increase of serum zinc levels in initially hypozincemic dialysis patients causes a reversible increase of serum AP. The result is compatible with some tissue zinc deficiency in hypozincemic dialysis patients.     

Selective Plasma Exchange With Dialysis in Patients With Acute Liver Failure

Selective plasma exchange with dialysis is a blood purification therapy in which simple plasma exchange is performed using a selective membrane plasma separator while the dialysate flows out of the hollow fibers. To evaluate the effect of plasma exchange with dialysis, biochemical examination of the blood, for example, the oxidative stress regulation system and interleukin 18 levels, was performed in patients with acute liver failure. We studied four patients with acute liver failure in whom the therapy was performed (nine times in total). The degree of hepatic encephalopathy and interleukin 18 levels decreased significantly after treatment. However, total protein levels did not change significantly. The level of reactive oxygen species and total antioxidant capacity did not change significantly. Plasma exchange with dialysis may be a useful blood purification therapy in cases of acute liver failure in terms of the removal of water‐soluble and albumin‐bound toxins.     

Dialysate Vascular Endothelial Growth Factor Is an Independent Determinant of Serum Albumin Levels and Predicts Future Withdrawal From Peritoneal Dialysis in Uremic Patients

Peritoneal protein loss due to high peritoneal permeability may contribute to hypoalbuminemia and early withdrawal from peritoneal dialysis (PD) therapy in end stage renal disease (ESRD) patients. We have found that pigment epithelium‐derived factor (PEDF) has anti‐vasopermeability properties both in cell culture and animal models by counteracting the biological actions of vascular endothelial growth factor (VEGF). However, it remains unknown which clinical variables, including dialysate VEGF and PEDF, are associated with decreased serum albumin levels and could predict early withdrawal from the PD in ESRD patients. We address these issues. Twenty‐seven ESRD patients undergoing PD were enrolled. Clinical variables were measured at 6 months after commencing PD. We examined the independent correlates of serum albumin in PD patients and then prospectively investigated the predictors of withdrawal from the PD therapy over 4 years. Dialysate VEGF was associated with peritoneal solute transport rate (P = 0.002), serum albumin (inversely, P < 0.001) and dialysate PEDF levels (P < 0.001). In multiple stepwise regression analysis, age (P = 0.002) and dialysate VEGF levels (P < 0.001) were independent determinants of serum albumin levels. High VEGF (>27 pg/mL), low serum albumin (≤3.31 g/dL) and low hemoglobin (≤11.2 g/dL) were correlated with withdrawal from the PD therapy during the 4 years. The odds ratio of dialysate VEGF for early withdrawal from the PD was 6.310 (P = 0.035). The present study demonstrated that increased dialysate VEGF was associated with decreased serum albumin and early withdrawal from the PD therapy. Inhibition of peritoneal VEGF production may be a therapeutic target in PD patients.     

miR-24对氧化低密度脂蛋白诱导血管内皮细胞炎症损伤的影响

目的 探讨microRNA-24(miR-24)对氧化低密度脂蛋白(Ox-LDL)诱导人脐静脉内皮细胞(HUVECs)炎症损伤的影响及潜在分子机制.方法 采用细胞计数试剂盒(CCK-8)法检测HUVECs的增殖;Transwell试验检测HUVECs的迁移能力;实时荧光定量聚合酶链反应(qRT-PCR)检测miR-24...     

'Clean dialysate' requires not only lower levels of endotoxin but also sterility of dilution water

Clean dialysate should be used in dialysis with a high-flux dialysis membrane to avoid contamination of endotoxin into blood circuits. For this purpose, we should not only clean up the end stream dialysate by endotoxin-cut filters, but also prevent bacterial growth in dilution water lines. Delivery lines of the prepared dialysate from a central dialysate-supplying machine are sterilized in all dialysis facilities, but those of the dilution water in cases of using personal dialysis machines are not sterilized in most facilities in Japan. In our dialysis department, the endotoxin level in the dilution water lines decreased to <50 EU/l in 3 weeks by sterilization with a low concentration of sodium hypochlorite (30-100 ppm) once a week from the peak level of >1,000 EU/l just after the start of sterilization.     

脑卒中患者的溶血磷酯酸与氧化低密度脂蛋白测定

目的探讨血浆溶血磷脂酸(LPA)与氧化低密度脂蛋白(Ox-LDL)相关性及其在脑卒中早期诊断中的价值。方法随机选择32例短暂脑缺血发作患者,31例脑梗死患者测定其血浆LPA、血清LDL和Ox-LDL水平,30例健康人作为对照组,并对结果作相关性分析。结果短暂脑缺血发作患者,脑梗死患者血浆LPA和Ox-LDL水平增高,与对照组有显著性差异(P<0.01),且二者呈正相关,相关系数(r)分别为0.623、0.65。结论LPA和Ox-LDL在脑卒中患者中具有相关性,且可作为早期预警指标。